Clinical observation of esomeprazole combined with trimebutine on treatment of non-erosive reflux disease
10.3760/cma.j.issn.1008-6315.2014.02.017
- VernacularTitle:埃索美拉唑联合马来酸曲美布汀治疗非糜烂性反流病的临床观察
- Author:
Xiaobin YANG
;
Tao SUN
;
Xin LI
;
Guangzhou GAO
;
Wenya ZHU
- Publication Type:Journal Article
- Keywords:
Non-erosive reflux disease;
Esomeprazole;
Trimebutine;
Mosapride
- From:
Clinical Medicine of China
2014;30(2):168-170
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect and recurrence of the esomeprazole combined with trimebutine on treatment for non-erosive reflux disease(NERD).Methods One hundred and twenty-five cases of patients with NERD were randomly divided into the treatment group (n =62) and the control group (n =63).Patients in treatment group were received the esomeprazole 20 mg,twice a day and trimebutine 0.2 g,3 times a day,in control group were received the esomeprazole 20 mg,twice a day and mosapride 5 mg,3 times a day.After 8 weeks treatment,6 months follow-up was conducted and the effects and recurrence were evaluated.Results The clinical curative rates at 4th and 8th weeks treatment in treatment group were 75.8％ (47/62) and 95.2％ (59/62),higher than that of control group (57.1％ (36/63),x2 =4.879,P =0.027 ; 84.1％ (53/63),x2 =4.083,P =0.043).The GERDQ curative rates at 4th and 8th weeks treatment in treatment group were 72.6％ (45/62),93.5％ (58/62) respectively,significantly higher than that of the control group (52.4％ (33/ 63),x2 =5.434,P =0.020 ; 79.4％ (50/63),x2 =5.350,P =0.021).The recurrence rates of 6 months followup were 77.4％ (48/62) in the treatment group and 81.0％ (51/63) in the control group,there was no significant difference between the two groups (P =0.627).Conclusion Esomeprazole combined with trimebutine is safe and effective treatment on non-erosive reflux disease,and the recurrence rates was lower than that in the control group.
